Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3075 - Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

Date

10 Sep 2017

Session

Poster display session

Presenters

Ana Molina

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

A.M. Molina1, P.J. Christos2, Y. Whang3, L. Nordquist4, A.L. Hackett1, H. Beltran1, B. Faltas1, D. Nanus1, P. Giannakakou1, S.T. Tagawa1

Author affiliations

  • 1 Hematology And Medical Oncology, Weill Cornell Medical College, 10065 - New York/US
  • 2 Biostatistics And Epidemiology, Weill Cornell Medical College, 10065 - New York/US
  • 3 Medical Oncology/lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 27599 - Chapel Hill/US
  • 4 Medical Oncology, Urology Cancer Center and GU Research Network, 68130 - Omaha/US
More

Resources

Abstract 3075

Background

Androgen receptor (AR) targeted therapy is the mainstay of treatment for PC, with potent AR signaling inhibitors and CYP17 inhibitors leading to improved survival. Taxanes are the only chemotherapy class to demonstrate a survival benefit in prospective randomized studies. Docetaxel (D), inhibits AR trafficking from the cytoplasm to the nucleus via stabilizing microtubules, suggesting D may complement AR-pathway targeted therapies. Recent randomized studies showing a > 1 year median survival benefit in men treated with the combination of effective direct AR-targeted therapy combined with D, suggesting that “vertical pathway blockade” in which combinations of AR-directed therapies with complementary mechanisms of action are more effective than sequential use (Sweeney NEJM 2015, James Lancet 2016). Two phase 3 trials are testing the combination of AR signaling inhibitors and CYP17 inhibitors. The safety of combining D with AA is pts with mCRPC was demonstrated in the COU-AA-206 (Tagawa Eur Urol 2016). Combinations of therapies targeting different pathways have the potential to improve efficacy.

Trial design

A multicenter phase 1 dose-escalation study will be conducted to determine the maximum tolerated dose (MTD) of ARN (novel AR signaling inhibitor) combined with AA (CYP17 inhibitor) and D (taxane) in chemotherapy-naïve mCRPC pts with ECOG performance status 0-2. Following determination of MTD, a cohort expansion at the recommended Phase 2 dose will occur. Starting doses are 120 mg/day ARN with 1000 mg/day AA, D 75 mg/m2 every 3 weeks, and prednisone 5 mg BID. Upon completion of D, pts may continue ARN and AA. The primary endpoint is the safety and tolerability of ARN when dosed with AA and D. Tumor tissue will be collected prospectively to evaluate exploratory biomarkers predictive of response and resistance. In addition, pre- and post-treatment circulating tumor cells will be interrogated for AR localization and AR splice variants. Circulating tumor DNA will also be collected pre- and post-therapy to explore resistance mechanisms.

Clinical trial identification

NCT02913196

Legal entity responsible for the study

Weill Cornell Medical College

Funding

Janssen Scientific Affairs, LLC

Disclosure

A.M. Molina: Consulting for Novartis, EISAI and Exelixis. Research funding from Janssen. Y. Whang: Research funding from Janssen, Astellas, Tokai and Inovio. H. Beltran: Consultant for Janssen and Sanofi. Research funding from Janssen. D. Nanus: Genentech Roche (DSMB). S.T. Tagawa: Research funding and consulting from Janssen. Research funding and consulting from Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.